Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patients with advanced (inoperable) non-squamous non-small cell lung cancer (NSCLC) from solely platinum-based chemotherapy to more personalized treatment, including targeted therapies and immunotherapies. However, these improvements come at considerable costs, highlighting the need to assess their cost-effectiveness in order to optimize lung cancer care. Traditionally, cost-effectiveness models for the evaluation of new lung cancer treatments were based on the findings of the randomized control tria... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Schlagwörter: | Humans / Antineoplastic Agents/adverse effects / Netherlands / Cost-Benefit Analysis / Lung Neoplasms/drug therapy / Carcinoma / Non-Small-Cell Lung/drug therapy / Antineoplastic Combined Chemotherapy Protocols/therapeutic use / Competing risks / Multicenter / Tyrosine kinase inhibitors / Survival outcomes / Cost-effectiveness analysis / Chemotherapy / Pembrolizumab / Simulation / Immunotherapy / 1st-line therapy / General |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26836912 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://dspace.library.uu.nl/handle/1874/427599 |